Scholar Rock (NASDAQ:SRRK) posted its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.08, Fidelity Earnings reports. The company had revenue of $3.11 million during the quarter, compared to the consensus estimate of $5.05 million.
SRRK stock traded down $0.63 during mid-day trading on Wednesday, reaching $18.97. The company had a trading volume of 528 shares, compared to its average volume of 80,730. The company has a market cap of $516.75 million and a price-to-earnings ratio of -6.02. Scholar Rock has a 52 week low of $13.09 and a 52 week high of $30.00.
An institutional investor recently raised its position in Scholar Rock stock. Geode Capital Management LLC raised its stake in Scholar Rock Holding Corp (NASDAQ:SRRK) by 54.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,988 shares of the company’s stock after purchasing an additional 28,276 shares during the quarter. Geode Capital Management LLC owned approximately 0.32% of Scholar Rock worth $1,837,000 at the end of the most recent reporting period. 51.64% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Scholar Rock (SRRK) Releases Earnings Results, Beats Estimates By $0.08 EPS” was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/05/15/scholar-rock-srrk-releases-earnings-results-beats-estimates-by-0-08-eps.html.
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Recommended Story: What is Call Option Volume?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.